Tyrosine kinases play significant roles in tumor progression and therapy resistance. Inhibitors of tyrosine kinases are on the forefront of targeted therapy. For prostate cancer, tyrosine kinases play an additional role in the development of castration-resistant disease state, the most troubling aspect of prostate cancinogenesis which presently defies any effective treatment. Among the 30 or so...

Cancer is one of the most common diseases in world. Th e transcription factor NF-κB plays a key role various physiological processes including immune response, cell proliferation, apoptosis and inflammation. Due to participation NF-kappa B signaling pathways carcinogenesis, angiogenesis, tumor resistance chemo- radiotherapy, considered be ideal target for pharmacological treatment cancer. paper...

PURPOSE The vascular endothelial growth factor receptor-2 (VEGFR2) tyrosine kinase has been implicated in the pathologic angiogenesis associated with tumor growth. YM-359445 was a (3Z)-3-quinolin-2(1H)-ylidene-1,3-dihydro-2H-indol-2-one derivative found while screening based on the inhibition of VEGFR2 tyrosine kinase. The aim of this study was to analyze the efficacy of this compound both in v...

evidence acquisition the fifty two significant articles discussing the stem cell in chronic myeloid leukemia from 1996 to 2012 were selected according to the authors’ experience. results studies have shown that primitive cml cells are less responsive to tyrosine kinase inhibitors (tkis) and are a reservoir for the relapse of multi drug resistant (mdr). conclusions following that, minimal residu...

Difficult to detect, ovarian cancer typically presents at an advanced stage. Significant progress has been achieved in the treatment of ovarian cancer with therapeutics focused on DNA replication or cell division. However, despite sensitivity to induction chemotherapy the majority of patients will develop recurrent disease. Conventional agents for recurrent disease offer little in terms of long...

The treatment of chronic myelogenous leukemia (CML) was revolutionized by the development of imatinib mesylate, a small molecule inhibitor of several protein tyrosine kinases, including the ABL1 protein tyrosine kinase. The current second generation of FDA-approved ABL tyrosine kinase inhibitors, dasatinib and nilotinib, are more potent inhibitors of BCR-ABL1 kinase in vitro. Originally approve...